CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $465 | -9.5% | 10,251 | +12.0% | 0.00% | 0.0% |
| Q2 2023 | $514 | +21.5% | 9,156 | -2.1% | 0.00% | +100.0% |
| Q1 2023 | $423 | +16.2% | 9,354 | +4.6% | 0.00% | 0.0% |
| Q4 2022 | $364 | -99.9% | 8,944 | -0.2% | 0.00% | -50.0% |
| Q3 2022 | $586,000 | +2.8% | 8,961 | -4.4% | 0.00% | 0.0% |
| Q2 2022 | $570,000 | +8.8% | 9,378 | +12.3% | 0.00% | 0.0% |
| Q1 2022 | $524,000 | +23.6% | 8,354 | +49.3% | 0.00% | +100.0% |
| Q4 2021 | $424,000 | -41.1% | 5,594 | -13.1% | 0.00% | -50.0% |
| Q3 2021 | $720,000 | -61.9% | 6,434 | -44.9% | 0.00% | -60.0% |
| Q2 2021 | $1,891,000 | +268.6% | 11,678 | +177.7% | 0.01% | +400.0% |
| Q1 2021 | $513,000 | +48.7% | 4,206 | +86.8% | 0.00% | 0.0% |
| Q4 2020 | $345,000 | -58.1% | 2,252 | -83.9% | 0.00% | -75.0% |
| Q2 2018 | $824,000 | -28.7% | 14,028 | -44.5% | 0.00% | -20.0% |
| Q1 2018 | $1,156,000 | – | 25,298 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |